FRM
XENE icon

Fox Run Management’s Xenon Pharmaceuticals XENE Stock Holding History

Fox Run Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,372
Closed -$382K – 1293
2025
Q1 		$382K Buy
11,372
+2,751
+32% +$104K 0.06% 600
2024
Q4 		$338K Sell
8,621
-11,123
-56% -$460K 0.06% 589
2024
Q3 		$777K Buy
19,744
+13,057
+195% +$526K 0.17% 203
2024
Q2 		$261K Buy
+6,687
New +$267K 0.05% 585
2024
Q1 		– Sell
-6,595
Closed -$304K – 1103
2023
Q4 		$304K Buy
+6,595
New +$233K 0.08% 488
2023
Q1 		– Sell
-12,975
Closed -$512K – 964
2022
Q4 		$512K Buy
12,975
+3,244
+33% +$118K 0.21% 168
2022
Q3 		$351K Buy
+9,731
New +$350K 0.14% 300

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fox Run Management's XENE Position: Q2 2025 in Review

Fox Run Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 11,372 shares — an estimated $382K sold.

Fox Run Management first reported a position in XENE in Q3 2022 and held it in 7 quarters. The position peaked at $777K in Q3 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Fox Run Management reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Fox Run Management sold 11,372 Xenon Pharmaceuticals shares in Q2 2025, an estimated $382K.
  • Fox Run Management first reported a position in Xenon Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Fox Run Management's Xenon Pharmaceuticals position peaked at $777K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.